Inventurus Knowledge Solutions Limited has informed the Exchange regarding a press release dated July 31, 2025, titled "Press Release Financial Results (Standalone and Consolidated) for the quarter ended June 30, 2025.".
IKS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
IKS Health reported strong Q1 FY26 results for the quarter ended June 30, 2025, with consolidated revenue of ₹7,401 million, up 15.6% year-on-year and 2.2% quarter-on-quarter (13% YoY in USD terms). EBITDA grew 36.3% YoY to ₹2,378 million, with margin expanding to 32.1% of revenue. Profit after tax (PAT) surged 58.7% YoY to ₹1,515 million, with PAT margin at 20.5%, while adjusted PAT rose 51.4% YoY to ₹1,682 million. The company announced new client partnerships with Mission Community Hospital and Bicycle Health, and expanded existing relationships with OrthoNY and a top 5 US health system. IKS Health also won multiple industry awards including ET HRWorld Exceptional Employee Experience and BW Finance & Strategy Excellence Awards.
Strong broad-based growth across revenue, profitability, and margins signals healthy business momentum and pricing power. The combination of double-digit revenue growth, expanding EBITDA margins, and nearly 59% PAT growth is likely to be viewed positively by the market, potentially supporting the stock price. New and expanded client wins in the US healthcare market also reinforce the long-term growth thesis.